Isoastragaloside I

Synonyms: 异黄芪皂苷I; Isoastragaloside-I
Isoastragaloside I 是一种从黄芪中发现的天然化合物,具有口服活性及抗炎、抗氧化等多种生物活性,可抑制 Akt、NF-κB、MAPKs、PI3K,增强肝脏 FXR 活性,调控 TGF-β/Smads 信号通路,上调 Nrf2 下游抗氧化分子,抑制 NO、TNF-α、iNOS、COX-2、IL-1β、VCAM-1 的表达并降低细胞内 ROS 水平,同时可减轻血脑屏障破坏、恢复肠屏障功能、增加 β 细胞量、改善葡萄糖稳态、提升循环脂联素水平,因此可用于研究与神经炎症相关的神经退行性疾病、胆汁淤积性肝病及糖尿病。
产品编号: MS-Y23410 纯度: 99.49% CAS No.: 84676-88-0 分子式: C45H72O16 分子量: 869.04
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Isoastragaloside I 是一种从黄芪中发现的天然化合物,具有口服活性及抗炎、抗氧化等多种生物活性,可抑制 Akt、NF-κB、MAPKs、PI3K,增强肝脏 FXR 活性,调控 TGF-β/Smads 信号通路,上调 Nrf2 下游抗氧化分子,抑制 NO、TNF-α、iNOS、COX-2、IL-1β、VCAM-1 的表达并降低细胞内 ROS 水平,同时可减轻血脑屏障破坏、恢复肠屏障功能、增加 β 细胞量、改善葡萄糖稳态、提升循环脂联素水平,因此可用于研究与神经炎症相关的神经退行性疾病、胆汁淤积性肝病及糖尿病。

生物实验数据

生物活性 Isoastragaloside I is a natural compound found in Astragalus membranaceus that possesses oral activity and multiple biological activities such as anti-inflammatory and antioxidant effects; it inhibits Akt, NF-κB, MAPKs, and PI3K, enhances hepatic FXR activity, regulates the TGF-β/Smads signaling pathway, upregulates Nrf2 downstream antioxidant molecules, suppresses the expression of NO, TNF-α, iNOS, COX-2, IL-1β, and VCAM-1, and reduces intracellular ROS levels, while also alleviating blood-brain barrier disruption, restoring intestinal barrier function, increasing β-cell mass, improving glucose homeostasis, and elevating circulating adiponectin levels, and can therefore be used for research on neuroinflammation-related neurodegenerative diseases, cholestatic liver disease, and diabetes.
IC50 & Target

Akt

 

NF-κB

 

p38 MAP kinase

 

PI3K

 

iNOS

 

COX-2

 

IL-1β

 

体外研究
(In Vitro)

Isoastragaloside I (ISO I) (5-100 μM; 24 h) 对 BV-2 小胶质细胞无细胞毒性作用。
Isoastragaloside I (25-100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可剂量依赖性地抑制 LPS 诱导的 BV-2 小胶质细胞分泌 NO 和 TNF-α。
Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 iNOS 和 COX-2 蛋白表达,NF-κB、IκBα、p38、JNK 和 ERK1/2 的磷酸化。
Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可下调 BV-2 小胶质细胞中 LPS 诱导的 TNF-α、IL-1β 及 iNOS mRNA 的表达。
Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 NF-κB 反式激活活性。阻断 LPS 诱导的 BV-2 小胶质细胞中磷酸化 NF-κB 的核转位。
Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 5-30 min LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 PI3K 和 Akt 磷酸化。
Isoastragaloside I (ISOI) (25-100 μM; 2 h pre-incubation, 1-24 h co-treatment with LPS) 预处理可抑制 LPS 诱导的 bEnd.3 细胞 TEER 降低。
Isoastragaloside I (25-100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可减轻 LPS 诱导的 bEnd.3 细胞中 Na+F− 渗出,降低 ROS 累积,恢复紧密连接蛋白 (ZO-1、occludin、claudin-5) 的表达。
Isoastragaloside I (25-100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可降低 LPS 诱导的 JAWS II 单核细胞与 bEnd.3 细胞的黏附作用。
Isoastragaloside I 预处理可降低脂多糖 (LPS) 诱导的 bEnd.3 细胞中 IL-1β、TNF-α、VCAM-1 和 ICAM-1 的 mRNA 表达水平。
Isoastragaloside I (100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可抑制 LPS 诱导的 bEnd.3 细胞中 VCAM-1 蛋白表达,恢复 LPS 降低的 bEnd.3 细胞中 Nrf2、HO-1 和 NQO1 蛋白表达。
Isoastragaloside I (25-100 μM; 24 h) 可激活 HEK293T 细胞中 Nrf2 的反式激活作用。
Isoastragaloside I (100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可增强 LPS 处理后 bEnd.3 细胞中被抑制的 Nrf2 核转位。
Isoastragaloside I (100 μM; 2 h pre-incubation, 12 or 24 h co-treatment with LPS after Nrf2 siRNA transfection) 预处理恢复 LPS 刺激的 bEnd.3 细胞紧密连接蛋白表达和 VCAM-1 表达的能力依赖于 Nrf2 信号通路,因为沉默 Nrf2 会消除该效应。
Isoastragaloside I (10 μM) 可在体外抑制胰腺导管类器官生长,而低剂量则不会改变类器官细胞的增殖。

Cell Viability Assay

Cell Line: BV-2 microglial cells
Concentration: 25, 50, 100 μM
Incubation Time: 24 h
Result: Did not alter the viability of BV-2 cells.

Western Blot Analysis

Cell Line: LPS-stimulated BV-2 microglial cells
Concentration: 100 μM
Incubation Time: 2 h pre-treatment, followed by 20 h LPS stimulation
Result: Reduced LPS-triggered iNOS and COX-2 protein expression, and suppressed the phosphorylation of NF-κB and IκBα.
Mitigated LPS-induced activation of p38, JNK and ERK1/2.

Real Time qPCR

Cell Line: LPS-stimulated BV-2 microglial cells
Concentration: 100 μM
Incubation Time: 2 h pre-treatment, followed by 20 h LPS stimulation
Result: Significantly reduced LPS-induced mRNA expression of TNF-α, IL-1β, and iNOS.

Western Blot Analysis

Cell Line: LPS-stimulated BV-2 microglial cells
Concentration: 100 μM
Incubation Time: 2 h pre-treatment, followed by 5, 15, or 30 min LPS stimulation
Result: Significantly attenuated LPS-induced phosphorylation of PI3K and Akt across all time points tested.

Western Blot Analysis

Cell Line: mouse brain endothelial bEnd.3 cells
Concentration: 100 μM
Incubation Time: 2 h pre-incubation; 24 h co-treatment with LPS
Result: Rescued LPS-induced reductions of ZO-1, occludin, and claudin-5 protein expression, with significant restoration of occludin and claudin-5 levels, and visible restoration of ZO-1 membrane localization.
Restrained LPS-induced elevation of VCAM-1 protein levels and restored LPS-mediated downregulation of Nrf2, HO-1 and NQO1 protein expression.

Immunofluorescence

Cell Line: mouse brain endothelial bEnd.3 cells
Concentration: 100 μM
Incubation Time: 2 h pre-incubation; 24 h co-treatment with LPS
Result: Increased nuclear Nrf2 fluorescence intensity, indicating enhanced Nrf2 nuclear translocation.

Western Blot Analysis

Cell Line: mouse brain endothelial bEnd.3 cells
Concentration: 100 μM
Incubation Time: 2 h pre-incubation; 12 or 24 h co-treatment with LPS, after Nrf2 siRNA transfection
Result: No longer exerted a significant effect on ZO-1, occludin, or claudin-5 levels when Nrf2 was silenced.\nDid not reverse LPS-induced VCAM-1 expression elevation when Nrf2 was silenced.
体内研究
(In Vivo)

Isoastragaloside I (IAS I) (20-50 mg/kg;口服;每日;4 周) 可剂量依赖性地缓解 DDC 诱导的 C57BL/6J 小鼠胆汁淤积性肝病,在肝损伤、纤维化、炎症、胆汁酸代谢及肠屏障功能方面均有显著改善。
Isoastragaloside I (IAS-I) (0.5-5 mg/kg;静脉注射;第 0-21 天) 可使健康小鼠的小胰岛质量显著增加约 60%;缓解 1 型糖尿病小鼠和 2 型糖尿病小鼠的症状并增加小胰岛质量。

Animal Model: C57BL/6J (male, 8 weeks old, 18-20 g, DDC diet-induced cholestatic liver disease)
Dosage: 20 mg/kg; 50 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Increased body weight dose-dependently compared to the DDC model group.
Reduced liver weight and liver/body weight ratio significantly.
Reduced intraluminal porphyrin embolism, inflammatory cell aggregation, and portal duct reaction via H&E staining.
Reduced collagen deposition significantly via Sirius Red staining.
Dose-dependently reduced levels of alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, and total bile acid compared to the DDC model group.
Reduced liver hydroxyproline content and Sirius Red-positive area significantly.
Reduced positive areas and mRNA/protein expression of cholangiocyte biomarkers cytokeratin 19 and cytokeratin 7 significantly.
Reduced positive area and mRNA/protein expression of α-smooth muscle actin significantly.
Reduced mRNA expression of collagen type I alpha 1 chain, collagen type IV, and transforming growth factor-β1 significantly.
Reduced protein expression of TGF-β1 and phosphorylated Smad2/3 (p-Smad2/3)/Smad2/3 significantly.
Reduced positive area and mRNA expression of F4/80 significantly.
Reduced mRNA expression of tumor necrosis factor-α and interleukin-1β significantly.
Reduced protein expression of interleukin-6 and CD68 significantly.
Reduced levels of arachidonic acid metabolites 5-hydroxyeicosatetraenoic acid, 15-HETE, 11(S)-HETE, prostaglandin E2, prostaglandin D2, 14(15)-DiHET, and 11(12)-DiHET significantly.
Increased levels of ω-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid significantly.
Increased fecal bile acid concentrations, including tau-BAs, gly-BAs, uncon-BAs, and total BAs significantly.
Normalized serum and liver bile acid profiles, with significant reductions in total BAs, uncon-BAs, con-BAs, and tau-BAs compared to the DDC model group.
Increased liver levels of taurocholic acid, taurohyocholic acid, taurodeoxycholic acid, and taurochenodeoxycholic acid significantly.
Increased mRNA expression of hepatic farnesoid X receptor, small heterodimer partner, cholesterol 7α-hydroxylase, sodium taurocholate cotransport peptide, and bile-salt export pump significantly.
Increased protein expression of FXR and Cyp7a1 significantly.
Improved colonic mucosal structural integrity, reduced inflammatory cell infiltration, and restored goblet cell count.
Increased positive area and mRNA expression of zonula occludens protein 1 significantly.
Increased mRNA expression of Occludin and Muc2 significantly.
Increased protein expression of Occludin significantly.
Animal Model: ICR and C57BL/6 (8-week-old, healthy)
Dosage: 0.5 mg/kg; 5 mg/kg
Administration: i.v.; days 0, 3, 7, 10, 14, 17, 21
Result: Induced a statistically significant ~60% increase in small islet mass compared to controls at 0.5 mg/kg.
Showed a non-significant trend towards increased total β-cell proportion and total β-cell mass at both doses.
Animal Model: C57BL/6 (6-week-old, type 2 diabetes induced by 3 months high-fat diet + 3 consecutive daily i.p. 50 mg/kg streptozotocin, blood glucose >16.7 mM on two consecutive days)
Dosage: 0.5 mg/kg; 5 mg/kg
Administration: i.v.; days 0, 3, 7, 10, 14, 17, 21
Result: Alleviated hyperglycaemia at both doses without affecting body weight.
Improved insulin resistance only at 0.5 mg/kg (~40% AUC reduction), but not at 5 mg/kg, and did not improve glucose responsiveness at either dose.
Increased small islet mass at both doses, with a non-significant trend towards increased total β-cell mass.
Animal Model: ICR (8-week-old, type 1 diabetes induced by single i.p. 150 mg/kg Streptozotocin (MS-Q80520), blood glucose >16.7 mM on two consecutive days)
Dosage: 0.5 mg/kg
Administration: i.v.; days 0, 3, 7, 10, 14, 17, 21
Result: Reduced fasting blood glucose without affecting body weight or glucose responsiveness.
Increased β-cell proportion and total β-cell mass in the pancreas, as well as β-cell proportion in both small and large islets.
Found that proliferating β-cells accounted for only 0.009% of total pancreatic cells, indicating the increase in β-cell mass was not primarily mediated by β-cell proliferation.
Animal Model: SOX9-CreERT2; R26-LSL-tdTomato (type 1 diabetes induced by single i.p. 150 mg/kg streptozotocin, blood glucose >16.7 mM on two consecutive days; ductal cells labelled via 5 consecutive daily i.p. 75 mg/kg tamoxifen (MS-L29547) prior to diabetes induction)
Dosage: 0.5 mg/kg
Administration: i.v.; days 0, 3, 7, 10, 14, 17, 21
Result: Alleviated hyperglycaemia compared to controls.
Showed co-localization of tdTomato+ duct-derived cells with Insulin+ β-cells in islets and small islets, and significantly increased the proportion of duct-derived Insulin+ cells to 3.1% of total tdTomato+ cells compared to controls.
Resulted in proliferating β-cells almost exclusively arising from SOX9-derived cells.
性状 固体
颜色 White to yellow

化学信息

分子量 869.04
分子式 C45H72O16
CAS No. 84676-88-0
别名 异黄芪皂苷I; Isoastragaloside-I

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (0.58 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (57.53 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.1507 mL5.7535 mL11.5070 mL28.7674 mL
5 mM0.2301 mL1.1507 mL2.3014 mL5.7535 mL
10 mM0.1151 mL0.5753 mL1.1507 mL2.8767 mL
15 mM0.0767 mL0.3836 mL0.7671 mL1.9178 mL
20 mM0.0575 mL0.2877 mL0.5753 mL1.4384 mL
25 mM0.0460 mL0.2301 mL0.4603 mL1.1507 mL
30 mM0.0384 mL0.1918 mL0.3836 mL0.9589 mL
40 mM0.0288 mL0.1438 mL0.2877 mL0.7192 mL
50 mM0.0230 mL0.1151 mL0.2301 mL0.5753 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

异黄芪皂苷 I;异黄芪苷 I 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础